BamSEC and AlphaSense Join Forces
Learn More

Paratek Pharmaceuticals Inc.

Formerly NASDAQ: PRTK
Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.1
from 8-K 6 pages Paratek Pharmaceuticals, Inc. and U.S. Bank Trust Company, National Association as Trustee, First Supplemental Indenture Dated as of September 21, 2023 to Indenture Dated as of April 23, 2018 4.75% Convertible Senior Subordinated Notes Due 2024
12/34/56
EX-10.2
from 8-K 15 pages Voting and Support Agreement
12/34/56
EX-10.1
from 8-K 19 pages Form of Contingent Value Rights Agreement
12/34/56
EX-10.48
from 10-K 5 pages Amendment Agreement – Amendment No.5 to the Product Agreement Dated July 28, 2017
12/34/56
EX-10.42
from 10-K 4 pages Treats as Private or Confidential. Sixth Amendment to the Amended and Restated Manufacturing and Services Agreement
12/34/56
EX-10.37
from 10-K 2 pages Third Amendment to the Manufacturing and Services Agreement
12/34/56
EX-10.21
from 10-K 73 pages This Lease (This “Lease”) Is Entered Into as of January 23, 2015, Between Atlantic American Properties Trust, a Maryland Real Estate Investment Trust (“Landlord”), and Paratek Pharmaceuticals LLC, a Delaware Limited Liability Company (“Tenant”). in Consideration of the Mutual Covenants Stated Below, and Intending to Be Legally Bound, the Parties Covenant and Agree as Follows: 1. Summary of Key Defined Terms
12/34/56
EX-10.2
from 10-Q 8 pages Material contract
12/34/56
EX-10.1
from 10-Q 72 pages Material contract
12/34/56
EX-10.45
from 10-K 5 pages This Exhibit Has Been Redacted and Is the Subject of a Confidential Treatment Request. Redacted Material Is Marked With [* * *] and Has Been Filed Separately With the Securities and Exchange Commission. Amendment Agreement – Amendment No.4 to the Product Agreement Dated July 28, 2017
12/34/56
EX-10.40
from 10-K 4 pages This Exhibit Has Been Redacted and Is the Subject of a Confidential Treatment Request. Redacted Material Is Marked With [* * *] and Has Been Filed Separately With the Securities and Exchange Commission. Fifth Amendment to the Amended and Restated Manufacturing and Services Agreement
12/34/56
EX-10.9
from 10-K 2 pages Paratek Pharmaceuticals, Inc. Non-Employee Director Compensation Policy
12/34/56
EX-10.6A
from 10-K 18 pages Paratek Pharmaceuticals, Inc. 2017 Inducement Plan, as Amended Adopted: June 15, 2017 Amended: October 16, 2018 Amended: March 9, 2022
12/34/56
EX-10.3
from 10-Q 10 pages Certain Confidential Information Contained in This Document, Marked With [***], Has Been Omitted Because It Is Both (I) Not Material and (II) Is the Type That the Registrant Treats as Private or Confidential
12/34/56
EX-10.2
from 10-Q 11 pages Certain Confidential Information Contained in This Document, Marked With [***], Has Been Omitted Because It Is Both (I) Not Material and (II) Is the Type That the Registrant Treats as Private or Confidential
12/34/56
EX-10.1
from 10-Q 48 pages Supply Agreement Between Paratek Pharmaceuticals, Inc. and Carbogen Amcis AG Date July 14, 2021
12/34/56
EX-10.50
from 10-K 10 pages Certain Confidential Information Contained in This Document, Marked With [***], Has Been Omitted Because It Is Both (I) Not Material and (II) Is the Type That the Registrant Treats as Private or Confidential
12/34/56
EX-10.14
from 10-K 62 pages Certain Confidential Information Contained in This Document, Marked With [***], Has Been Omitted Because It Is Both (I) Not Material and (II) Is the Type That the Registrant Treats as Private or Confidential
12/34/56
EX-10.9
from 10-K 2 pages Paratek Pharmaceuticals, Inc. Non-Employee Director Compensation Policy
12/34/56
EX-10.12
from 8-K 8 pages Certain Confidential Information Contained in This Document, Marked With [***], Has Been Omitted Because It Is Both (I) Not Material and (II) Would Be Competitively Harmful if Publicly Disclosed. Amendment Agreement ‑ Amendment No.3 to the Product Agreement Dated July 28, 2017
12/34/56